ifosfamide has been researched along with Infection in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 9.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| " Based on the limited clinical impact and the high incidence of rhGM-CSF-related toxicity that required growth factor discontinuation, the routine administration of rhGM-CSF to prevent neutropenia and infection after ifosfamide-based chemotherapy for GCT patients is not recommended." | 5.08 | Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. ( Bajorin, DF; Bokemeyer, C; Bosl, GJ; Demetri, GD; Einhorn, LH; Kantoff, PW; Nichols, CR; Schmoll, HJ, 1995) |
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 5.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| "Grade 3 and 4 infections occurred four times more frequently in the dose-dense arm." | 2.75 | Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. ( Chott, A; Drach, J; Fridrik, MA; Geissler, D; Greil, R; Hausmaninger, H; Krieger, O; Lang, A; Michlmayr, G; Oberaigner, W; Ulsperger, E, 2010) |
| " After adjusting for body size, AUC0-6 and Cmax were positively related to dose (P = 0." | 2.71 | Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. ( Beane, C; Boddy, AV; Brennan, B; Chisholm, JC; Cole, M; Elsworth, AM; Errington, J; Glaser, A; Hale, J; Hemsworth, S; Howe, K; Jenner, G; McDowell, H; Nicholson, J; Parry, A; Pearson, AD; Pinkerton, R; Pritchard-Jones, K; Veal, GJ; Waters, F; Wright, Y, 2005) |
| "Fungal, viral, and nosocomial infections were uncommon." | 1.35 | Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. ( Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM, 2008) |
| "Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)." | 1.33 | IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| " Poor performance status and prior radiotherapy were risk factors for fatal adverse effects." | 1.30 | [Treatment of advanced testicular cancer and toxicity of chemotherapy]. ( Kawakita, M; Matsuda, T; Terachi, T; Yoshida, O, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fridrik, MA | 1 |
| Hausmaninger, H | 1 |
| Lang, A | 1 |
| Drach, J | 1 |
| Krieger, O | 1 |
| Geissler, D | 1 |
| Michlmayr, G | 1 |
| Ulsperger, E | 1 |
| Chott, A | 1 |
| Oberaigner, W | 1 |
| Greil, R | 1 |
| Caglar, K | 1 |
| Kinalp, C | 1 |
| Arpaci, F | 1 |
| Turan, M | 1 |
| Saglam, K | 1 |
| Ozturk, B | 1 |
| Komurcu, S | 1 |
| Yavuz, I | 1 |
| Yenicesu, M | 1 |
| Ozet, A | 1 |
| Vural, A | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Abali, H | 1 |
| Oyan, B | 1 |
| Koc, Y | 1 |
| Kars, A | 1 |
| Barista, I | 1 |
| Uner, A | 1 |
| Turker, A | 1 |
| Demirkazik, F | 1 |
| Tekin, F | 1 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Veal, GJ | 1 |
| Cole, M | 1 |
| Errington, J | 1 |
| Parry, A | 1 |
| Hale, J | 1 |
| Pearson, AD | 1 |
| Howe, K | 1 |
| Chisholm, JC | 1 |
| Beane, C | 1 |
| Brennan, B | 1 |
| Waters, F | 1 |
| Glaser, A | 1 |
| Hemsworth, S | 1 |
| McDowell, H | 1 |
| Wright, Y | 1 |
| Pritchard-Jones, K | 1 |
| Pinkerton, R | 1 |
| Jenner, G | 1 |
| Nicholson, J | 1 |
| Elsworth, AM | 1 |
| Boddy, AV | 1 |
| Jathavedam, A | 1 |
| Feldman, DR | 1 |
| Ishill, N | 1 |
| Turkula, S | 1 |
| Patil, S | 1 |
| Bosl, GJ | 2 |
| Motzer, RJ | 1 |
| Weinstock, DM | 1 |
| Bajorin, DF | 1 |
| Nichols, CR | 1 |
| Schmoll, HJ | 1 |
| Kantoff, PW | 1 |
| Bokemeyer, C | 1 |
| Demetri, GD | 1 |
| Einhorn, LH | 2 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Kawakita, M | 1 |
| Matsuda, T | 1 |
| Terachi, T | 1 |
| Yoshida, O | 1 |
| García-Rayo, S | 1 |
| Pérez-Calvo, J | 1 |
| Martín-Algarra, S | 1 |
| Martínez-Monge, R | 1 |
| Fernández-Hidalgo, O | 1 |
| Subirá, L | 1 |
| Martínez-Aguillo, M | 1 |
| Rebollo, J | 1 |
| Azinovic, I | 1 |
| Brugarolas, A | 1 |
| Lee, EJ | 1 |
| Petroni, GR | 1 |
| Schiffer, CA | 1 |
| Freter, CE | 1 |
| Johnson, JL | 1 |
| Barcos, M | 1 |
| Frizzera, G | 1 |
| Bloomfield, CD | 1 |
| Peterson, BA | 1 |
| Bramwell, VH | 1 |
| Mouridsen, HT | 1 |
| Santoro, A | 1 |
| Blackledge, G | 1 |
| Somers, R | 1 |
| Thomas, D | 1 |
| Sylvester, R | 1 |
| Van Oosterom, A | 1 |
| Loehrer, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma[NCT00517894] | 0 participants | Expanded Access | No longer available | ||||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Infection
| Article | Year |
|---|---|
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
7 trials available for ifosfamide and Infection
| Article | Year |
|---|---|
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2010 |
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat | 2005 |
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; | 1995 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections; | 1986 |
6 other studies available for ifosfamide and Infection
| Article | Year |
|---|---|
Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Alkyla | 2002 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F | 2005 |
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H | 2008 |
[Treatment of advanced testicular cancer and toxicity of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Germinoma; Humans; | 1999 |
Ifosfamide chemotherapy for pancreatic carcinoma.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam | 1986 |